The phase III IMbrave150 trial evaluating the combination of the PD-L1 inhibitor atezolizumab plus bevacizumab has recently represented an important step forward in the medical management of HCC [1]. According to the results of this study, advanced HCC patients receiving atezolizumab – bevacizumab reported statistically significant and clinically meaningful improvements in terms of overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and complete response rate, compared with sorafenib monotherapy
Rizzo A., Ricci A.D., Brandi G. (2022). Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma. EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 7(1), 1-3 [10.1080/23808993.2022.2020091].
Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma
Ricci A. D.;Brandi G.
2022
Abstract
The phase III IMbrave150 trial evaluating the combination of the PD-L1 inhibitor atezolizumab plus bevacizumab has recently represented an important step forward in the medical management of HCC [1]. According to the results of this study, advanced HCC patients receiving atezolizumab – bevacizumab reported statistically significant and clinically meaningful improvements in terms of overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and complete response rate, compared with sorafenib monotherapyI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
